3Rizos L. Three-year survival of patients with heart failure caused by dilated cardiomyopathy and L-carnitine administration[J]. Am J Cardiol,2000,139(2Pt3):121-123.
二级参考文献21
1[1]Jackson G. Combination therapy in angina: a review of combined haemodynamic treatment and the role for combined haemodynamic and cardiac metabolic agents. Int J Clin Pract, 2001,55:256-61.
2[2]Stanley WC, Lopaschnk GD, Hall JL, et al. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions. Cardiovas Res,1997, 33:243-57.
3[3]Kantor PF, Lucien A, Kozak R, et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res, 2000,86:580-8.
4[4]McClellan KL, Ploaker GL. Trimetazidine.. A review of its use in stable angina pectoris and other coronary conditions. Drugs, 1999,58 : 143-57.
5[5]Szwed H, Sadowski Z, Pachocki R, et al. Efficacy and safety of trimetazidine in patients with persistent stable angina pectoris under beta-blocker therapy , TRIMPOL II multicentre study. Eur Heart J,1999, 20 :Abstract 2516.
6[6]Belarcation R. Trimetazidine and the contractile response of dysfunctional myocardium in ischemic cardiomyopathy. Rev Port Carciol, 2000; 19: V35-9.
7[7]Brottier L, Barat JL, Combe C, et al. Therapeutic value of a cardioprotective agent in patients with severe ischemic cardiomyopathy.Eur Heart J, 1990, 11:207-12.
8[8]Lu C, Dabrowski P, Fragasso G, et al. Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease. Am J Cardio , 1998, 82:898-901.
9[9]Belardinelli R, Purcaro A. Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischemic cardiomyopathy. Eur Heart J, 2000, 22:2164-70.
10[10]P Di Napoli,A A Taccard,A Barsotti, et al. Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy. Heart,2005,91:161-5.
3Olson TM,Terzic A,Human K,et al.ATP channelopathies:diseases of metabolichomeostasis[J].Pflugers Arch,2010,460(2):295-306.
4全国心肌病心肌炎专研讨会纪要[J].临床心血管病杂志,1995,11(6):324-326.
5Higgins JPT,Green S (editors).Cochrane Handbook for System-atic Reviews of Interventions Version 5.1.0[updated Macch 2011].The Cochrane Collaboration,2011.
6Kosmicki M.Metabolic drugs in treatment of iscaemic heart disease[J].Doctors Guided,2001,(1):57-64.
7Rizos L.Three-year survival of patients with heart failure caused by dilated cardiomyopathy and L-carnitine administration[J].Am Heart J,2000,139(2 Pt 3):121-123.
